Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying ethical issues in stepped-wedge cluster randomized trials to inform the Ottawa Statement update: a systematic review of trials published 2016-2022.

Journal of clinical epidemiology·2025
Same author

Gaps in the Ottawa Statement on the Ethical Design and Conduct of Cluster Randomized Trials: a citation analysis reveals a need for updated ethics guidelines.

Research integrity and peer review·2025
Same author

Should Children Be Included in Human Challenge Studies?

Ethics & human research·2024
Same author

Ethical challenges in research on sexual dysfunction.

Bioethics·2023
Same author

Ethical and practical considerations related to data sharing when collecting patient-reported outcomes in care-based child health research.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2023
Same author

SARS-CoV-2 challenge studies: ethics and risk minimisation.

Journal of medical ethics·2020

Related Experiment Video

Updated: Jun 29, 2026

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

Rethinking risk in pediatric research.

Kathleen Cranley Glass1, Ariella Binik

  • 1Biomedical Ethics Unit, McGill University.

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|October 9, 2008
PubMed
Summary
This summary is machine-generated.

This review examines pediatric research, highlighting concerns about allowable risk levels in studies involving children. It calls for careful oversight to protect young participants while advancing medical care.

More Related Videos

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

Related Experiment Videos

Last Updated: Jun 29, 2026

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
07:01

A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)

Published on: February 7, 2025

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure
15:18

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

Area of Science:

  • Pediatric Research Ethics
  • Clinical Trial Oversight

Background:

  • The inclusion of children in clinical research is crucial for addressing pediatric health needs and eliminating the

Purpose of the Study:

  • To review four key areas in pediatric research where allowable risk levels may exceed established guidelines.
  • To ensure ethical standards in pediatric research are maintained.
  • To balance the need for pediatric medical advancements with participant safety.

Main Methods:

  • Review of existing pediatric research protocols and federal panel review applications.
  • Analysis of risk categorization in research involving children.
  • Examination of research designs, including placebo-controlled trials and studies on asymptomatic at-risk children.

Main Results:

  • Identified questionable risk levels in pediatric research protocols.
  • Observed an increase in research applications for higher-risk studies requiring federal review.
  • Noted concerns regarding the inclusion of children in placebo-controlled trials without subgroup analysis.

Conclusions:

  • While including children in research is vital for medical progress, current practices raise ethical concerns regarding acceptable risk.
  • Recommendations for stricter oversight and ethical review are necessary to protect pediatric participants.
  • Further investigation into risk stratification and subgroup analysis in pediatric trials is warranted.